DPP4 antibody refers to an antibody targeting dipeptidyl peptidase-4 (DPP4), a multifunctional transmembrane glycoprotein also known as CD26. DPP4 is a serine exopeptidase that cleaves X-proline or X-alanine dipeptides from the N-terminus of polypeptides, regulating hormones like glucagon-like peptide-1 (GLP-1) and chemokines . Antibodies against DPP4 are used to study its enzymatic activity, receptor function, and role in diseases such as diabetes, autoimmune disorders, and viral infections .
DPP4 exists as a dimeric membrane-bound protein or soluble form in plasma. Its enzymatic activity regulates glucose metabolism by degrading incretins, while its non-enzymatic roles include immune modulation via interactions with adenosine deaminase and cell-surface receptors .
Diabetes: Anti-DPP4 antibodies inhibit DPP4 enzymatic activity, elevating GLP-1 levels to improve insulin sensitivity. A peptide vaccine targeting DPP4 epitopes (E1, E3) reduced hyperglycemia in diabetic mice .
Autoimmune Diseases: DPP4 antibodies modulate immune cell activity (e.g., CD4+ T cells) and are linked to Graves' disease severity .
Antiviral Strategies: DPP4 antibodies block MERS-CoV entry by binding to the viral receptor-binding domain .
Western Blot (WB): Detects DPP4 at ~55–60 kDa in human and hamster tissues .
Immunohistochemistry (IHC): Localizes DPP4 in bronchial epithelium, kidney proximal tubules, and tumor cells .
Flow Cytometry: Identifies CD26 (DPP4) expression on T cells and dendritic cells .
DPP4 Vaccine for Diabetes: Immunization with E3-KLH conjugates in mice increased anti-DPP4 titers, inhibited plasma DPP4 activity by 60%, and improved insulin sensitivity without autoimmune toxicity .
MERS-CoV Inhibition: Polyclonal DPP4 antibodies reduced viral infection in human bronchial cells by 90% by blocking receptor binding .
Autoimmune Modulation: Elevated serum DPP4 activity correlates with Graves' disease severity, suggesting diagnostic potential .